Anyone who has invested in technology will be familiar with Moore's law. This eponymous theory proposed by the co-founder of Intel in 1965 stated that the processing performance of computers would double every two years due to advancements in chip design.
In the years since, it has proven uncannily accurate. However, when it comes to biotech, rates of progress have often left Moore's law for dust. Take genomic sequencing, for example. In 2003, the first whole human genome was sequenced via a laborious process that cost roughly $2.7 billion. Today, you can sequence the human genome for about $500. If Moore's law had been in play, this cost would be closer to $500,000. Investing in biotech: Where are we now and what is the outlook? Similar stories can be found in proteomics, ribonucleic acid (RNA) science, nanotech, sensors and Cr...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
